Avogaro A, Fadini GP, Del Prato S (2020) Reinterpreting cardiorenal protection of renal sodium-glucose cotransporter 2 inhibitors via cellular life history programming. Diabetes Care 43:501–507

Article  Google Scholar 

Baartscheer A, Schumacher CA, Wust RC, Fiolet JW, Stienen GJ, Coronel R, Zuurbier CJ (2017) Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits. Diabetologia 60:568–573

CAS  Article  Google Scholar 

Bell RM, Yellon DM (2017) SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. Lancet Diabetes Endocrinol 6:435

Article  Google Scholar 

Bell RM, Yellon DM (2018) SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. Lancet Diabetes Endocrinol 6:435–437

Article  Google Scholar 

Bertero E, Prates Roma L, Ameri P, Maack C (2018) Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res 114:12–18

CAS  Article  Google Scholar 

Bravo-San Pedro JM, Kroemer G, Galluzzi L (2017) Autophagy and Mitophagy in Cardiovascular Disease. Circ Res 120:1812–1824

CAS  Article  Google Scholar 

Delbridge LMD, Mellor KM, Taylor DJ, Gottlieb RA (2017) Myocardial stress and autophagy: mechanisms and potential therapies. Nat Rev Cardiol 14:412–425

CAS  Article  Google Scholar 

Ferrannini E, Mark M, Mayoux E (2016) CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39:1108–1114

Article  Google Scholar 

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW et al (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25:486–541

Article  Google Scholar 

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S et al (2015) Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242

CAS  Article  Google Scholar 

Greene SJ, Vaduganathan M, Khan MS, Bakris GL, Weir MR, Seltzer JH, Sattar N, McGuire DK, Januzzi JL, Stockbridge N et al (2018) Prevalent and incident heart failure in cardiovascular outcome trials of patients with Type 2 diabetes. J Am Coll Cardiol 71:1379–1390

Article  Google Scholar 

Hariharan N, Maejima Y, Nakae J, Paik J, Depinho RA, Sadoshima J (2010) Deacetylation of FoxO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes. Circ Res 107:1470–1482

CAS  Article  Google Scholar 

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589

CAS  Article  Google Scholar 

Kobayashi S, Xu X, Chen K, Liang Q (2012) Suppression of autophagy is protective in high glucose-induced cardiomyocyte injury. Autophagy 8:577–592

CAS  Article  Google Scholar 

Lavandero S, Chiong M, Rothermel BA, Hill JA (2015) Autophagy in cardiovascular biology. J Clin Invest 125:55–64

Article  Google Scholar 

Liu CY, Zhang YH, Li RB, Zhou LY, An T, Zhang RC, Zhai M, Huang Y, Yan KW, Dong YH et al (2018) LncRNA CAIF inhibits autophagy and attenuates myocardial infarction by blocking p53-mediated myocardin transcription. Nat Commun 9:29

Article  Google Scholar 

Liu Y, Shoji-Kawata S, Sumpter RM Jr, Wei Y, Ginet V, Zhang L, Posner B, Tran KA, Green DR, Xavier RJ et al (2013) Autosis is a Na+, K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. Proc Natl Acad Sci USA 110:20364–20371

CAS  Article  Google Scholar 

Lopaschuk GD, Verma S (2016) Empagliflozin’s fuel hypothesis: not so soon. Cell Metab 24:200–202

CAS  Article  Google Scholar 

Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI (2017) Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 136:1643–1658

CAS  Article  Google Scholar 

Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, Paulus WJ, Rossignol P, Taegtmeyer H, Bauersachs J et al (2018) Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J 39:4243–4254

CAS  Article  Google Scholar 

Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T, Levine B, Sadoshima J (2007) Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res 100:914–922

CAS  Article  Google Scholar 

McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995

CAS  Article  Google Scholar 

Mudaliar S, Alloju S, Henry RR (2016) Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis. Diabetes Care 39:1115–1122

CAS  Article  Google Scholar 

Nah J, Zhai P, Huang CY, Fernandez AF, Mareedu S, Levine B, Sadoshima J (2020) Upregulation of Rubicon promotes autosis during myocardial ischemia/reperfusion injury. J Clin Invest 130:2978–2991

CAS  Article  Google Scholar 

Nakamura TY, Iwata Y, Arai Y, Komamura K, Wakabayashi S (2008) Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure. Circ Res 103:891–899

CAS  Article  Google Scholar 

Nassif M, Kosiborod M (2018) Effect of glucose-lowering therapies on heart failure. Nat Rev Cardiol 15:282–291

CAS  Article  Google Scholar 

Nassif ME, Windsor S, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire D, Pitt B, Scirica BM, Austin B et al (2019) Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF Trial. Circulation 140:1463

CAS  Article  Google Scholar 

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657

CAS  Article  Google Scholar 

Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471

CAS  Article  Google Scholar 

Packer M (2017) Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation 136:1548–1559

CAS  Article  Google Scholar 

Packer M (2020a) Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium-glucose cotransporter 2 inhibitors. Eur J Heart Fail 22:618–628

CAS  Article  Google Scholar 

Packer M (2020b) SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care 43:508–511

CAS  Article  Google Scholar 

Packer M, Anker SD, Butler J, Filippatos G, Zannad F (2017) Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2:1025–1029

Article  Google Scholar 

Perry RJ, Rabin-Court A, Song JD, Cardone RL, Wang Y, Kibbey RG, Shulman GI (2019) Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun 10:548

CAS  Article  Google Scholar 

Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E, Garcia-Ropero A, Sanz J, Hajjar RJ et al (2019) Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol 73:1931–1944

CAS  Article  Google Scholar 

Santulli G (2018) Cardioprotective effects of autophagy: eat your heart out, heart failure! Sci Transl Med. https://doi.org/10.1126/scitranslmed.aau0462

Article  Google Scholar 

Sciarretta S, Forte M, Frati G, Sadoshima J (2018a) New insights into the role of mTOR signaling in the cardiovascular system. Circ Res 122:489–505

CAS  Article  Google Scholar 

Sciarretta S, Maejima Y, Zablocki D, Sadoshima J (2018b) The role of autophagy in the heart. Annu Rev Physiol 80:1–26

CAS  Article  Google Scholar 

Sciarretta S, Yee D, Nagarajan N, Bianchi F, Saito T, Valenti V, Tong M, Del Re DP, Vecchione C, Schirone L et al (2018c) Trehalose-induced activation of autophagy improves cardiac remodeling after myocardial infarction. J Am Coll Cardiol 71:1999–2010

CAS  Article  Google Scholar 

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326

CAS  Article  Google Scholar 

Taylor SI, Blau JE, Rother KI (2015) Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 3:8–10

CAS  Article  Google Scholar 

Todd AE, Orengo CA, Thornton JM (2001) Evolution of function in protein superfamilies, from a structural perspective. J Mol Biol 307:1113–1143

CAS  Article  Google Scholar 

Ueda P, Svanstrom H, Melbye M, Eliasson B, Svensson AM, Franzen S, Gudbjornsdottir S, Hveem K, Jonasson C, Pasternak B (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363:k4365

Article  Google Scholar 

Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R et al (2018) Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia 61:722–726

CAS  Article  Google Scholar 

Vettor R, Inzucchi SE, Fioretto P (2017) The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. Diabetologia 60:395–398

CAS  Article  Google Scholar 

Wang D, Hu X, Lee SH, Chen F, Jiang K, Tu Z, Liu Z, Du J, Wang L, Yin C et al (2018) Diabetes exacerbates myocardial ischemia/reperfusion injury by down-regulation of microRNA and up-regulation of O-GlcNAcylation. JACC Basic Transl Sci 3:350–362

Article  Google Scholar 

Wang Y, Meyer JW, Ashraf M, Shull GE (2003) Mice with a null mutation in the NHE1 Na+-H+ exchanger are resistant to cardiac ischemia-reperfusion injury. Circ Res 93:776–782

CAS  Article  Google Scholar 

Whelan RS, Kaplinskiy V, Kitsis RN (2010) Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 72:19–44

CAS  Article  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA et al (2019) Dapagliflozin an